



## Pyxis Oncology to Participate in Two Upcoming Investment Conferences

August 31, 2023

BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced its participation in two upcoming investment conferences.

On September 6, 2023, members of the Pyxis Oncology executive team will host in-person 1x1 meetings with investors during the 2023 Wells Fargo Healthcare Conference in Boston. To schedule a meeting, please reach out to your Wells Fargo representative or contact Investor Relations at [IR@pyxisoncology.com](mailto:IR@pyxisoncology.com).

On September 11, 2023, a pre-recorded presentation by Lara S. Sullivan, M.D., President and Chief Executive Officer, will be made available via [webcast](#) as part of the H.C. Wainwright 25<sup>th</sup> Annual Global Investment Conference beginning at 7:00 AM EST. In addition, the Pyxis Oncology executive team will host 1x1 meetings with investors via Zoom. To schedule a meeting, please reach out to your H.C. Wainwright representative or contact Investor Relations.

For additional information on Pyxis Oncology, please visit [pyxisoncology.com](http://pyxisoncology.com).

### About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono and combination therapies. Pyxis Oncology's therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Pyxis Oncology's antibody-drug conjugates (ADCs) and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care. To learn more, visit [www.pyxisoncology.com](http://www.pyxisoncology.com) or follow us on [Twitter](#) and [LinkedIn](#).

### Forward-Looking Statements

*This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "likely," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "to be," "will," "would," or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled "Risk Factors" set forth in Part II, Item 1A. of the Company's Annual Report on Form 10-K filed with SEC on March 22, 2023 and in our other filings with the SEC. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.*

### Pyxis Oncology Contact

Jennifer Davis Ruff  
VP, Investor Relations  
[jdavisruff@pyxisoncology.com](mailto:jdavisruff@pyxisoncology.com)